
At HelioWave, we’re proud to partner with forward-thinking investors who share our vision of creating impactful innovations.
HelioWave is backed by funding from ARPA-H, DARPA, NIH, and USDA, with additional support from Capital Factory, BioTools Innovator, BARDA Blue Knight, and JLABS. These resources accelerate our mission to transform microbial quality control testing through innovative technologies that enhance product safety, streamline regulatory compliance, and improve biomanufacturing efficiency.
HelioWave has utilized non-diluted government funding to support the research activities. Funding includes:
HelioLIFE: Automated, Low-cost Integrated Fluidics Enabled platform for final product release testing
ARPA-H SBIR (Phase I)
Contract: 140D0426C0013
Year Start: 2026
HelioSAFE: A Platform for the Fast, Label-Free, Automated Evaluation of Sterility
DARPA SBIR (Phase I/II)
Contract: HR001121C0178, HR001122C014
Year Start: 2021
HelioQUANT: A Platform for Fast, Label-Free, Automated Evaluation of Bioburden
NIH SBIR (Phase I)
Contract: 1R43AI167567-01A1
Year Start: 2022
HelioCLEAN: Miniaturized system for rapid monitoring of food borne pathogens
USDA SBIR (Phase I)
Contract: USDA-2025-00518
Year Start: 2025
Currently in: Pre-seed stage funding
To accelerate commercialization and business development beyond government-funded R&D
Status: Open
Use of Fund: Workflow adaptation and MVP production (50%), commercial pilot deployment (35%), and ISO-compliant manufacturing trials (15%)
Milestones: MVP Finalization, Pilot Completion, and Revenue Generation

Stay ahead of HelioWave’s latest milestones, insights, and news by subscribing to our investor newsletter. Receive updates directly in your inbox, including:
Please contact us for latest pitch deck and access to our data room.